FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ı, D.C. 20549	OMB APPROVAL

OMB Number:	3235-028									
Estimated average burden										
hours per response:	0.									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* West Linda						2. Issuer Name and Ticker or Trading Symbol Galera Therapeutics, Inc. [GRTX]								heck all a X Dire	pplicable) ector cer (give titl	J	rson(s) to Iss 10% O Other (wner
	LERA THE	RAPEUTICS, II	APEUTICS, INC., 06/15/2021								Day/Year)			bel	ow)		below)	
	ERTY BLV	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) MALVERN PA 19355															Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(St	tate) ((Zip)															
		Tab	le I - Nor	า-Deri\	/ative	Sec	curitie	s Ac	quired,	Dis	posed o	of, or Be	neficia	lly Owr	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)						Execution Date,			Code (Instr. 5)			ed (A) or str. 3, 4 and	5. Amount of Securities Beneficially Owned Follow Reported		Forr (D) (7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	unt (A) or (D)		Tran	nsaction(s) str. 3 and 4)			
Common Stock 06/15/2					5/2021	2021		P		10,000 A \$		\$9.13	3(1)	10,000		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Date,	4. Transa Code (i 8)				6. Date Ex Expiration (Month/Da	Date	Amount of		of S g e Security	8. Price Derivati Security (Instr. 5	derivati Securit	ve ies ially ng ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$8.9	06/16/2021			A		9,888		(2)	0	6/15/2031	Common Stock	9,888	\$0.00	9,8	88	D	

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$9.01 to \$9.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 2. This option shall vest and become exercisable on the earlier of June 16, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

Remarks:

/s/ Christopher Degnan,

Attorney-in-Fact for Linda

West

** Signature of Reporting Person Date

06/17/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.